AzTrials
AzTrials

Psoriasis PatientsNCT05961605

COVID-19 Associated With Psoriasis

An observational study of Psoriasis Patients and COVID-19, run by Gang Wang, MD at 12 sites in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients. Read more about this study

Who is it for?
Any age
Conditions the study is for
Psoriasis Patients, COVID-19
How many people
2,500 participants
Where
12 sitesChina
Study dates
15 Mar 2023to 30 Jul 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Psoriasis patients registered in the database from January 2018 to November 2022

Who may be able to join

  • No age limit, both male and female are accepted;
  • Psoriasis patients registered in the database;
  • Patients or their families can cooperate to complete the follow-up information survey (questionnaire, telephone, etc.) independently, and ensure the authenticity of the data provided.

Who cannot join

  • Patients are thought having conditions which are not appropriated for attending this clinical trial.

Trial locations and contacts

12 sites in 1 country.

GANG WANG, M.D. contact

13571991903

xjwgang@fmmu.edu.cn

CHEN YU contact

13571991903

12 sites in 1 country

China12 sites, 1 recruiting

  • The Second Hospital of Jilin University

    Changchun, Jilin, 130041

    Completed

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041

    Completed

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016

    Completed

  • Dalian Dermatosis Hospital

    Dalian, Liaoning, 116021

    Completed

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, 510091

    Completed

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, 730000

    Completed

  • Shanghai Skin Disease Hospital, Tongji University School of Medicine

    Shanghai, Shanghai Municipality, 200443

    Completed

  • The University of Hong Kong-Shenzhen Hospital

    Shenzhen, Shenzhen, 518053

    Completed

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, Tianjin Municipality, 300021

    Completed

  • People's Hospital of Xinjiang Uygur Autonomous Region，Xinjiang Key Laboratory of Dermatology Research

    Ürümqi, Xinjiang, 830001

    Completed

  • Xijing Hospital, The Fourth Military Medical University

    Xi'an, Shaanxi, 710032

    CHEN YU

    Recruiting

  • Xining First People's Hospital

    Xining, Qinghai, 810000

    Completed

Other trials in China

About this study

Official title: Retrospective Clinical Study of COVID-19 Associated With the Condition and Treatment of Patients With Chinese Psoriasis

A retrospective analysis based on database was conducted to evaluate the correlation between covid-19 infection and the condition and treatment of psoriasis patients.

Read the detailed description

Based on the patients registered in the psoriasis patient database of each center, the patients were followed up by telephone, and the severity of covid-19 infection, the change of psoriasis condition and the adjustment of treatment methods of psoriasis patients were collected for retrospective analysis.

Keywords
psoriasis, covid-19
Medical subject headings
COVID-19, Psoriasis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection

    The impact of SARS-CoV-2 infection on psoriasis in patients receiving different baseline therapies of psoriasis.

    Measured: March 15,2023 to May 30,2023

Secondary outcomes (1)

  1. Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection

    Univariate and multivariate analyses identify risk factors with psoriasis exacerbation/recurrence after SARS-CoV-2 infection

    Measured: March 15,2023 to May 30,2023

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2023
  2. Study start15 Mar 2023
  3. Primary completion30 May 2023
  4. Study completion30 Jul 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
2,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05961605
Sponsor's protocol ID
XJPF202303-PSO&COVID-19
Status last verified
Jul 2023
First submitted
25 Jul 2023
Last updated
1 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Liu Y, Xu Z, Zhou J, Chen A, Zhang J, Kang X, Jiang X, Lyu C, Shi C, Shi Y, Liu X, Li F, Yang B, Huang Y, Yu C, Wang G. Clinical characteristics and outcomes of psoriasis patients with COVID-19: A retrospective, multicenter cohort study in China. Chin Med J (Engl). 2024 Jul 20;137(14):1736-1743. doi: 10.1097/CM9.0000000000003024. Epub 2024 May 6.

    PubMed 38710539

Questions about this trial

What is this clinical trial studying?

An observational study of Psoriasis Patients and COVID-19, run by Gang Wang, MD at 12 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact GANG WANG, M.D. (13571991903, xjwgang@fmmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The recurrence/exacerbation of psoriasis following SARS-CoV-2 infection (time frame: March 15,2023 to May 30,2023). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05961605, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in